LVMH Recherche, the LVMH Beauty R&D division, has signed a strategic research partnership with biotech company Integrated Biosciences.
The multi-year deal will see the two companies work together to discover “novel chemical entities that target ageing at the molecular level”.
This will be achieved through Integrated Biosciences’ synthetic biology and artificial intelligence AI-based platform.
The state-of-the-art deep learning model can virtually screen molecules, identifying chemical compounds that “potently modulate age-related biological phenotypes”.
“Our partnership with Integrated Biosciences perfectly embodies our vision: to push the boundaries of scientific discovery in the service of innovation in beauty,” said Bruno Bavouzet, President of LVMH Recherche.
“This represents a unique opportunity to evaluate thousands of potential bioactives concurrently, revolutionising the pace of our research for the benefit of all our brands including our flagship–Maison Parfums Christian Dior.”
“By combining our skin research expertise with their AI and ageing research, we are taking a decisive step in understanding and molecularly addressing age-related cellular pathways.”
Integrated Biosciences was founded by scientists at MIT, Harvard University and the University of California Santa Barbara.
The biotech firm recently initiated a fundraiser led by Sutter Hill Ventures, which is known for the AI-driven discovery of novel senolytic compounds.
These are anti-ageing chemical entities that selectively clear ‘zombie’ cells – cells that have stopped functioning normally and can secrete harmful substances.
“This collaboration with LVMH Recherche represents a significant step forward in our shared commitment to combating ageing through cutting-edge science,” added Felix Wong, co-founder and CEO of Integrated Biosciences.
“Our combined efforts have the potential to unlock biologically functional products that could transform how people age.”